Se connecter

Bibliographies thématiques / Leukemia inhibitory factor / Articles de revues

Pour voir les autres types de publications sur ce sujet consultez le lien suivant : Leukemia inhibitory factor.

Articles de revues sur le sujet « Leukemia inhibitory factor »

Auteur : Grafiati

Publié le 4 juin 2021

Mis à jour le 25 juillet 2025

Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres

Choisissez une source :

Consultez les 50 meilleurs articles de revues pour votre recherche sur le sujet « Leukemia inhibitory factor ».

À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.

Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.

Parcourez les articles de revues sur diverses disciplines et organisez correctement votre bibliographie.

1

Nicola, Nicos A., and Jeffrey J. Babon. "Leukemia inhibitory factor (LIF)." Cytokine & Growth Factor Reviews 26, no. 5 (2015): 533–44. http://dx.doi.org/10.1016/j.cytogfr.2015.07.001.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

2

Metcalf, Donald. "The leukemia inhibitory factor (LIF)." International Journal of Cell Cloning 9, no. 2 (1991): 95–108. http://dx.doi.org/10.1002/stem.5530090201.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

3

Pehlivan, Melek, Ceyda Caliskan, Zeynep Yuce, and Hakkı Ogun Sercan. "Forced expression of Wnt antagonists sFRP1 and WIF1 sensitizes chronic myeloid leukemia cells to tyrosine kinase inhibitors." Tumor Biology 39, no. 5 (2017): 101042831770165. http://dx.doi.org/10.1177/1010428317701654.

Texte intégral

Résumé :

Chronic myeloid leukemia is a clonal myeloproliferative disorder that arises from the neoplastic transformation of the hematopoietic stem cell, in which the Wnt/β-catenin signaling pathway has been demonstrated to play an important role in disease progression. However, the role of Wnt signaling antagonists in therapy resistance and disease progression has not been fully investigated. We aimed to study the effects of Wnt/β-catenin pathway antagonists—secreted frizzled-related protein 1 and Wnt inhibitory factor 1—on resistance toward tyrosine kinase inhibitors in chronic myeloid leukemia. Respo

Styles APA, Harvard, Vancouver, ISO, etc.

4

Na, Bon Hyang, Thi Xoan Hoang та Jae Young Kim. "Hsp90 Inhibition Reduces TLR5 Surface Expression and NF-κB Activation in Human Myeloid Leukemia THP-1 Cells". BioMed Research International 2018 (2018): 1–8. http://dx.doi.org/10.1155/2018/4319369.

Texte intégral

Résumé :

Tumors highly express active heat shock protein 90 (Hsp90), which is involved in tumor survival and progression. Enhanced Toll-like receptor (TLR) 5 expression and signaling were reported to be associated with acute myeloid leukemia. In the present study, we investigated the possible modulatory effects of Hsp90 inhibitors on TLR5 expression and signaling in the human myeloid leukemia cell line THP-1. Cells were pretreated with various concentrations of the Hsp90 inhibitor geldanamycin (GA) or the Hsp70 inhibitor VER155008, followed by stimulation with bacterial flagellin. Flagellin-induced nuc

Styles APA, Harvard, Vancouver, ISO, etc.

5

Vanchieri, C. "Leukemia Inhibitory Factor Has Multiple Personalities." JNCI Journal of the National Cancer Institute 86, no. 4 (1994): 262. http://dx.doi.org/10.1093/jnci/86.4.262.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

6

Hinds, Mark G., Till Maurer, Jian-Guo Zhang, Nicos A. Nicola, and Raymond S. Norton. "Solution Structure of Leukemia Inhibitory Factor." Journal of Biological Chemistry 273, no. 22 (1998): 13738–45. http://dx.doi.org/10.1074/jbc.273.22.13738.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

7

Senturk, Levent M., and Aydin Arici. "Leukemia Inhibitory Factor in Human Reproduction." American Journal of Reproductive Immunology 39, no. 2 (1998): 144–51. http://dx.doi.org/10.1111/j.1600-0897.1998.tb00346.x.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

8

RAY, DAVID W., SONG-GUANG REN, and SHLOMO MELMED. "Leukemia Inhibitory Factor Regulates Proopiomelanocortin Transcriptiona." Annals of the New York Academy of Sciences 840, no. 1 (1998): 162–73. http://dx.doi.org/10.1111/j.1749-6632.1998.tb09560.x.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

9

Lass, Amir, Weishui Weiser, Alain Munafo, and Ernest Loumaye. "Leukemia inhibitory factor in human reproduction." Fertility and Sterility 76, no. 6 (2001): 1091–96. http://dx.doi.org/10.1016/s0015-0282(01)02878-3.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

10

Hilton, Douglas J., and Nicholas M. Gough. "Leukemia inhibitory factor: A biological perspective." Journal of Cellular Biochemistry 46, no. 1 (1991): 21–26. http://dx.doi.org/10.1002/jcb.240460105.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

11

McKenzie, RC, D. Paglia, S. Kondo, and DN Sauder. "A novel endogenous mediator of cutaneous inflammation: leukemia inhibitory factor." Acta Dermato-Venereologica 76, no. 2 (1996): 111–14. http://dx.doi.org/10.2340/0001555576111114.

Texte intégral

Résumé :

Keratinocytes produce a variety of cytokines, including leukemia inhibitory factor. We hypothesised that this cytokine may play a pro-inflammatory role in the skin and tested this hypothesis by injecting recombinant leukemia inhibitory factor (1-100 ng) into the ear pinnae of C3H/HeJ mice. To other groups of animals, we injected boiled leukemia inhibitory factor or phosphate-buffered saline (negative control) or 0.4 ng human interleukin-1 alpha as a positive control. Following injection of 100 ng leukemia inhibitory factor, ear thickness, measured by micrometer, increased 66% over controls at

Styles APA, Harvard, Vancouver, ISO, etc.

12

Uno, Kanako, Takeshi Inukai, Nobuhiko Kayagaki, et al. "TNF-related apoptosis-inducing ligand (TRAIL) frequently induces apoptosis in Philadelphia chromosome–positive leukemia cells." Blood 101, no. 9 (2003): 3658–67. http://dx.doi.org/10.1182/blood-2002-06-1770.

Texte intégral

Résumé :

Tumor necrosis factor (TNF)–related apoptosis-inducing ligand (TRAIL) and Fas ligand (FasL) have been implicated in antitumor immunity and therapy. In the present study, we investigated the sensitivity of Philadelphia chromosome (Ph1)–positive leukemia cell lines to TRAIL- or FasL-induced cell death to explore the possible contribution of these molecules to immunotherapy against Ph1-positive leukemias. TRAIL, but not FasL, effectively induced apoptotic cell death in most of 5 chronic myelogenous leukemia–derived and 7 acute leukemia–derived Ph1-positive cell lines. The sensitivity to TRAIL was

Styles APA, Harvard, Vancouver, ISO, etc.

13

Pepper, M. S., N. Ferrara, L. Orci, and R. Montesano. "Leukemia inhibitory factor (LIF) inhibits angiogenesis in vitro." Journal of Cell Science 108, no. 1 (1995): 73–83. http://dx.doi.org/10.1242/jcs.108.1.73.

Texte intégral

Résumé :

Using an in vitro model in which endothelial cells can be induced to invade a three-dimensional collagen gel to form capillary-like tubular structures, we demonstrate that leukemia inhibitory factor (LIF) inhibits angiogenesis in vitro. The inhibitory effect was observed on both bovine aortic endothelial (BAE) and bovine microvascular endothelial (BME) cell, and occurred irrespective of the angiogenic stimulus, which included basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF), the synergistic effect of the two in combination, or the tumor promoter phorbol myristat

Styles APA, Harvard, Vancouver, ISO, etc.

14

Conover, J. C., N. Y. Ip, W. T. Poueymirou, et al. "Ciliary neurotrophic factor maintains the pluripotentiality of embryonic stem cells." Development 119, no. 3 (1993): 559–65. http://dx.doi.org/10.1242/dev.119.3.559.

Texte intégral

Résumé :

Ciliary neurotrophic factor was discovered based on its ability to support the survival of ciliary neurons, and is now known to act on a variety of neuronal and glial populations. Two distant relatives of ciliary neurotrophic factor, leukemia inhibitory factor and oncostatin M, mimic ciliary neurotrophic factor with respect to its actions on cells of the nervous system. In contrast to ciliary neurotrophic factor, leukemia inhibitory factor and oncostatin M also display a broad array of actions on cells outside of the nervous system. The overlapping activities of leukemia inhibitory factor, onc

Styles APA, Harvard, Vancouver, ISO, etc.

15

Hanington, Patrick C., Shunmoogum A. Patten, Laura M. Reaume, Andrew J. Waskiewicz, Miodrag Belosevic, and Declan W. Ali. "Analysis of leukemia inhibitory factor and leukemia inhibitory factor receptor in embryonic and adult zebrafish (Danio rerio)." Developmental Biology 314, no. 2 (2008): 250–60. http://dx.doi.org/10.1016/j.ydbio.2007.10.012.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

16

Romo, Bianca, Zenaida Fuentes, Lois Randolph, et al. "Targeting the Leukemia Inhibitory Factor/Leukemia Inhibitory Factor Receptor Axis Reduces the Growth of Inflammatory Breast Cancer by Promoting Ferroptosis." Cancers 17, no. 5 (2025): 790. https://doi.org/10.3390/cancers17050790.

Texte intégral

Résumé :

Background: Inflammatory breast cancer (IBC) is a rare subtype of breast cancer accounting for 7% of breast cancer-related fatalities. There is an urgent need to develop new targeted treatments for IBC. The progression of IBC has been associated with alterations in growth factor and cytokine signaling; however, the function of the LIF (leukemia inhibitory factor)/LIFR (leukemia inhibitory factor receptor) cytokine pathway in the progression of IBC remains unknown. This study evaluated the role of LIFR signaling and tested the efficacy of the LIFR inhibitor EC359 in treating IBC. Methods: The u

Styles APA, Harvard, Vancouver, ISO, etc.

17

Okabe, M., Y. Kuni-eda, T. Sugiwura, et al. "Inhibitory effect of interleukin-4 on the in vitro growth of Ph1- positive acute lymphoblastic leukemia cells." Blood 78, no. 6 (1991): 1574–80. http://dx.doi.org/10.1182/blood.v78.6.1574.1574.

Texte intégral

Résumé :

Abstract We investigated the effect of recombinant human interleukin-4 (rhIL-4) on the in vitro growth of human leukemia cells in liquid culture and 3H- thymidine incorporation and found inhibitory effects on the growth of leukemic cells from patients with Ph1-positive acute lymphoblastic leukemia (Ph1 ALL) and three Ph1 ALL cell lines. However, no inhibitory effects were seen in Ph1-positive leukemic cell lines derived from patients with chronic myelogenous leukemia in blast crisis and various types of Ph1-negative leukemia cells, including B-lineage leukemia cells. In a flow cytometry assay

Styles APA, Harvard, Vancouver, ISO, etc.

18

Okabe, M., Y. Kuni-eda, T. Sugiwura, et al. "Inhibitory effect of interleukin-4 on the in vitro growth of Ph1- positive acute lymphoblastic leukemia cells." Blood 78, no. 6 (1991): 1574–80. http://dx.doi.org/10.1182/blood.v78.6.1574.bloodjournal7861574.

Texte intégral

Résumé :

We investigated the effect of recombinant human interleukin-4 (rhIL-4) on the in vitro growth of human leukemia cells in liquid culture and 3H- thymidine incorporation and found inhibitory effects on the growth of leukemic cells from patients with Ph1-positive acute lymphoblastic leukemia (Ph1 ALL) and three Ph1 ALL cell lines. However, no inhibitory effects were seen in Ph1-positive leukemic cell lines derived from patients with chronic myelogenous leukemia in blast crisis and various types of Ph1-negative leukemia cells, including B-lineage leukemia cells. In a flow cytometry assay of IL-4 r

Styles APA, Harvard, Vancouver, ISO, etc.

19

Vernallis, Ann B., Keith R. Hudson, and John K. Heath. "An Antagonist for the Leukemia Inhibitory Factor Receptor Inhibits Leukemia Inhibitory Factor, Cardiotrophin-1, Ciliary Neurotrophic Factor, and Oncostatin M." Journal of Biological Chemistry 272, no. 43 (1997): 26947–52. http://dx.doi.org/10.1074/jbc.272.43.26947.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

20

Metcalf, D. "The Unsolved Enigmas of Leukemia Inhibitory Factor." Stem Cells 21, no. 1 (2003): 5–14. http://dx.doi.org/10.1634/stemcells.21-1-5.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

21

Gulluoglu, Sukru, Mesut Sahin, Emre Can Tuysuz, et al. "Leukemia Inhibitory Factor Promotes Aggressiveness of Chordoma." Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics 25, no. 7 (2017): 1177–88. http://dx.doi.org/10.3727/096504017x14874349473815.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

22

AGHAJANOVA, LUSINE. "Leukemia Inhibitory Factor and Human Embryo Implantation." Annals of the New York Academy of Sciences 1034, no. 1 (2004): 176–83. http://dx.doi.org/10.1196/annals.1335.020.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

23

Metcalf, Donald. "Leukemia Inhibitory Factor—A Puzzling Polyfunctional Regulator." Growth Factors 7, no. 3 (1992): 169–73. http://dx.doi.org/10.3109/08977199209046921.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

24

GEARING, DAVID P. "Leukemia Inhibitory Factor: Does the Cap Fit?" Annals of the New York Academy of Sciences 628, no. 1 Negative Regu (1991): 9–18. http://dx.doi.org/10.1111/j.1749-6632.1991.tb17218.x.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

25

KURZROCK, RAZELLE, ZEEV ESTROV, MEIR WETZLER, JORDAN U. GUTTERMAN, and OSHE MTALPAZ. "LIF: Not Just a Leukemia Inhibitory Factor*." Endocrine Reviews 12, no. 3 (1991): 208–17. http://dx.doi.org/10.1210/edrv-12-3-208.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

26

Cornish, J., K. E. Callon, S. G. Edgar, and I. R. Reid. "Leukemia inhibitory factor is mitogenic to osteoblasts." Bone 21, no. 3 (1997): 243–47. http://dx.doi.org/10.1016/s8756-3282(97)00144-0.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

27

Tran, Ami, Kalman Kovacs, Lucia Stefaneanu, George Kontogeorgos, Bernd W. Scheithauer, and Shlomo Melmed. "Expression of leukemia inhibitory factor in craniopharyngioma." Endocrine Pathology 10, no. 2 (1999): 103–8. http://dx.doi.org/10.1007/bf02739822.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

28

Waring, Paul M., Roberto Romero, Nihay Laham, Ricardo Gomez, and Gregory E. Rice. "Leukemia inhibitory factor: Association with intraamniotic infection." American Journal of Obstetrics and Gynecology 171, no. 5 (1994): 1335–41. http://dx.doi.org/10.1016/0002-9378(94)90157-0.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

29

Weber, Marietta A., Silvia Schnyder-Candrian, Bruno Schnyder, et al. "Endogenous leukemia inhibitory factor attenuates endotoxin response." Laboratory Investigation 85, no. 2 (2004): 276–84. http://dx.doi.org/10.1038/labinvest.3700216.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

30

Lemons, Angela R., and Rajesh K. Naz. "Birth control vaccine targeting leukemia inhibitory factor." Molecular Reproduction and Development 79, no. 2 (2011): 97–106. http://dx.doi.org/10.1002/mrd.22002.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

31

Hemme, E., M. A. C. Depuydt, L. Delfos, J. Kuiper, and I. Bot. "Leukemia inhibitory factor receptor inhibition in atherosclerosis." Atherosclerosis 379 (August 2023): S36. http://dx.doi.org/10.1016/j.atherosclerosis.2023.06.784.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

32

Hanson, J. M., J. A. Mol, and B. P. Meij. "Expression of leukemia inhibitory factor and leukemia inhibitory factor receptor in the canine pituitary gland and corticotrope adenomas." Domestic Animal Endocrinology 38, no. 4 (2010): 260–71. http://dx.doi.org/10.1016/j.domaniend.2009.11.005.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

33

Reinart, Nina, Malgorzata Ciesla, Cornelia Rudolph, et al. "Macrophage Migration Inhibitory Factor (MIF) Promotes the Development of Murine Chronic Lymphocytic Leukemia (CLL)." Blood 112, no. 11 (2008): 27. http://dx.doi.org/10.1182/blood.v112.11.27.27.

Texte intégral

Résumé :

Abstract Introduction: Tumor formation results from a complex interplay between genetic/epigenetic alterations, cell cycle dysregulation and promotion by the tumor environment. Stimulation by extracellular survival factors is important for chronic lymphocytic leukemia (CLL), since the leukemic cells undergo spontaneous apoptosis when removed from their normal milieu. Since preliminary experiments demonstrated that macrophage migration inhibitory factor (MIF), a chemokine-like proinflammatory mediator and an intracellular regulator of growth and apoptosis, is overexpressed in human CLL, we inve

Styles APA, Harvard, Vancouver, ISO, etc.

34

Auernhammer, C. J., and S. Melmed. "Leukemia-Inhibitory Factor—Neuroimmune Modulator of Endocrine Function*." Endocrine Reviews 21, no. 3 (2000): 313–45. http://dx.doi.org/10.1210/edrv.21.3.0400.

Texte intégral

Résumé :

Abstract Leukemia-inhibitory factor (LIF) is a pleiotropic cytokine expressed by multiple tissue types. The LIF receptor shares a common gp130 receptor subunit with the IL-6 cytokine superfamily. LIF signaling is mediated mainly by JAK-STAT (janus-kinase-signal transducer and activator of transcription) pathways and is abrogated by the SOCS (suppressor-of cytokine signaling) and PIAS (protein inhibitors of activated STAT) proteins. In addition to classic hematopoietic and neuronal actions, LIF plays a critical role in several endocrine functions including the utero-placental unit, the hypothal

Styles APA, Harvard, Vancouver, ISO, etc.

35

Yokoyama, A., J. Okabe-Kado, A. Sakashita, et al. "Differentiation inhibitory factor nm23 as a new prognostic factor in acute monocytic leukemia." Blood 88, no. 9 (1996): 3555–61. http://dx.doi.org/10.1182/blood.v88.9.3555.bloodjournal8893555.

Texte intégral

Résumé :

Differentiation inhibitory factor (nm23 protein) inhibited the induction of differentiation of mouse myeloid leukemia M1 and WEHI-3BD+ and human erythroleukemia HEL, KU812, and K562 cells. Block of differentiation may be associated with the aggressive behavior of leukemia. To examine the role of nm23 in human myeloid leukemia, we investigated the relative levels of nm23-H1, nm23-H2, and c-myc transcripts in 42 patients with acute myelogenous leukemia (AML), and in 5 with chronic myelogenous leukemia at chronic phase by reverse transcriptase polymerase chain reaction. The expression of nm23-H1

Styles APA, Harvard, Vancouver, ISO, etc.

36

LI, Yong, Lizhou SUN, Denmei ZHAO, Jun OUYANG, and Mei XIANG. "Aberrant expression of leukemia inhibitory factor receptor (LIFR) and leukemia inhibitory factor (LIF) is associated with tubal pregnancy occurrence." TURKISH JOURNAL OF MEDICAL SCIENCES 45 (2015): 214–20. http://dx.doi.org/10.3906/sag-1307-103.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

37

Wysoczynski, Marcin, Katarzyna Miekus, Kacper Jankowski, et al. "Leukemia Inhibitory Factor: A Newly Identified Metastatic Factor in Rhabdomyosarcomas." Cancer Research 67, no. 5 (2007): 2131–40. http://dx.doi.org/10.1158/0008-5472.can-06-1021.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

38

Kurokawa, Mineo, Kinuko Mitani, Yoichi Imai, Seishi Ogawa, Yoshio Yazaki та Hisamaru Hirai. "The t(3;21) Fusion Product, AML1/Evi-1, Interacts With Smad3 and Blocks Transforming Growth Factor-β–Mediated Growth Inhibition of Myeloid Cells". Blood 92, № 11 (1998): 4003–12. http://dx.doi.org/10.1182/blood.v92.11.4003.

Texte intégral

Résumé :

Abstract The t(3;21)(q26;q22) chromosomal translocation associated with blastic crisis of chronic myelogenous leukemia results in the formation of the AML1/Evi-1 chimeric protein, which is thought to play a causative role in leukemic transformation of hematopoietic cells. Here we show that AML1/Evi-1 represses growth-inhibitory signaling by transforming growth factor-β (TGF-β) in 32Dcl3 myeloid cells. The activity of AML1/Evi-1 to repress TGF-β signaling depends on the two separate regions of the Evi-1 portion, one of which is the first zinc finger domain. AML1/Evi-1 interacts with Smad3, an i

Styles APA, Harvard, Vancouver, ISO, etc.

39

Kurokawa, Mineo, Kinuko Mitani, Yoichi Imai, Seishi Ogawa, Yoshio Yazaki та Hisamaru Hirai. "The t(3;21) Fusion Product, AML1/Evi-1, Interacts With Smad3 and Blocks Transforming Growth Factor-β–Mediated Growth Inhibition of Myeloid Cells". Blood 92, № 11 (1998): 4003–12. http://dx.doi.org/10.1182/blood.v92.11.4003.423a56_4003_4012.

Texte intégral

Résumé :

The t(3;21)(q26;q22) chromosomal translocation associated with blastic crisis of chronic myelogenous leukemia results in the formation of the AML1/Evi-1 chimeric protein, which is thought to play a causative role in leukemic transformation of hematopoietic cells. Here we show that AML1/Evi-1 represses growth-inhibitory signaling by transforming growth factor-β (TGF-β) in 32Dcl3 myeloid cells. The activity of AML1/Evi-1 to repress TGF-β signaling depends on the two separate regions of the Evi-1 portion, one of which is the first zinc finger domain. AML1/Evi-1 interacts with Smad3, an intracellu

Styles APA, Harvard, Vancouver, ISO, etc.

40

Patterson, B., A. Tjernlund, and J. Andersson. "Endogenous Inhibitors of HIV: Potent Anti-HIV Activity of Leukemia Inhibitory Factor." Current Molecular Medicine 2, no. 8 (2002): 713–22. http://dx.doi.org/10.2174/1566524023361817.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

41

Park, Hye-Rin, Hee-Jung Choi, Bo-Sung Kim, et al. "Paeoniflorin Enhances Endometrial Receptivity through Leukemia Inhibitory Factor." Biomolecules 11, no. 3 (2021): 439. http://dx.doi.org/10.3390/biom11030439.

Texte intégral

Résumé :

Despite advances in assisted reproductive technology, treatment for deficient endometrial receptivity is a major clinical unmet need. In our previous study, the water extract of Paeonia lactiflora Pall. enhanced endometrial receptivity in vitro and in vivo via induction of leukemia inhibitory factor (LIF), an interleukin (IL)-6 family cytokine. In the present study, we found that paeoniflorin, a monoterpene glycoside, is the major active compound of P. lactiflora. Paeoniflorin significantly improved the embryo implantation rate in a murine model of mifepristone (RU486)-induced implantation fai

Styles APA, Harvard, Vancouver, ISO, etc.

42

Estrov, Zeev, Moshe Talpaz, Meir Wetzler, and Razelle Kurzrock. "The Modulatory Hematopoietic Activities of Leukemia Inhibitory Factor." Leukemia & Lymphoma 8, no. 1-2 (1992): 1–7. http://dx.doi.org/10.3109/10428199209049811.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

43

REID, I. R., C. LOWE, J. CORNISH, et al. "Leukemia Inhibitory Factor: A Novel Bone-Active Cytokine*." Endocrinology 126, no. 3 (1990): 1416–20. http://dx.doi.org/10.1210/endo-126-3-1416.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

44

Knight, D., and T. Bai. "Roles for leukemia inhibitory factor in lung biology." Drug News & Perspectives 12, no. 5 (1999): 261. http://dx.doi.org/10.1358/dnp.1999.12.5.863620.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

45

Auernhammer, C. J. "Leukemia-Inhibitory Factor--Neuroimmune Modulator of Endocrine Function." Endocrine Reviews 21, no. 3 (2000): 313–45. http://dx.doi.org/10.1210/er.21.3.313.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

46

van den Bent, Martin J. "Prevention of Chemotherapy-Induced Neuropathy: Leukemia Inhibitory Factor." Clinical Cancer Research 11, no. 5 (2005): 1691–93. http://dx.doi.org/10.1158/1078-0432.ccr-05-0079.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

47

Ishizaki, Seiji, Takashi Murase, Yoshihisa Sugimura, et al. "Leukemia inhibitory factor stimulates vasopressin release in rats." Neuroscience Letters 359, no. 1-2 (2004): 77–80. http://dx.doi.org/10.1016/j.neulet.2004.02.019.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

48

McCoy, A. J., V. Staton, A. Van Donkelaar, J. N. Varghese, and P. M. Colman. "X-ray crystallographic studies of leukemia inhibitory factor." Acta Crystallographica Section A Foundations of Crystallography 49, s1 (1993): c113. http://dx.doi.org/10.1107/s0108767378096750.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

49

Gearing, David P. "Molecular characterization of the leukemia inhibitory factor receptor." Fresenius' Journal of Analytical Chemistry 343, no. 1 (1992): 14–15. http://dx.doi.org/10.1007/bf00331947.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

50

Cornish, J., C. Lowe, S. J. M. Skinner, et al. "Leukemia inhibitory factor: A novel bone-active cytokine." Bone and Mineral 10, no. 3 (1990): S290. http://dx.doi.org/10.1016/0169-6009(90)90322-7.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Nous offrons des réductions sur tous les plans premium pour les auteurs dont les œuvres sont incluses dans des sélections littéraires thématiques. Contactez-nous pour obtenir un code promo unique!